⌕
Replimune Group · REPL · Nasdaq
Tenet 28 · Weak
Compare
$21.89−0.41%At closeTenet 28 · Weak
$21.89−0.09 (−0.41%)
At close: Nov 13, 2026, 4:00 PM ET· Nasdaq · USD

Replimune Group (REPL) Stock

Replimune Group (REPL) closed at $21.89 on Nov 13, 2026; its Tenet Score is 28 of 100 against 297 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

34 figures withheld by our checks. Each blank figure names its reason.

Key stats

Previous close
$21.89
Nov 13, 2026
Market cap
$2.1B
share price × the latest quarter's diluted weighted-average share count (vendor)
52-week range
1.50 – 23.54
low → high · as of close, Nov 13, 2026
Tenet Score
28/100
Weak · 297 Healthcare peers

Industry: Health Services

Replimune Group Inc scores 28/100. Weak. Quality is the soft spot versus 297 Healthcare peers. Insufficient inputs: Tenet 28 is built from 3 of 4 pillars, from 35% of its inputs. The pillars showing a dash had no data.

Tenet Score · vs sector

n=297
28/ 100
Weak
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
17
Quality
4
Health
62
Growth
—

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
Growth omitted — no data yet.
ValueFQualityFHealthCGrowth—MomentumB
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/E
—
Not meaningful: the company made a loss.
P/B
10.1×
price to book value
P/S
—
no P/S on file
ROE
−116%
return on equity
Operating margin
—
no operating margin on file
Net margin
—
Not meaningful: revenue is too small to measure a margin against.
Current ratio
7.11
current assets to liabilities
Net debt / EBITDA
—
Not meaningful: EBITDA is zero or negative.
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.
Div yield
—
no yield on file

The whole report, at a glance · every card is a live peek, click any to open the section

About Replimune Group Inc

Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. The…

Composite computed Nov 13, 2026 · peer basis: Healthcare (n=297) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 52 US ETFs · top wrappers by weightSee all ETFs holding REPL →

Similar-sized companies in Health Services

The 10 companies in this industry closest in market cap, as of Nov 13, 2026.

What sector and industry is Replimune Group in?

Replimune Group is in the Healthcare sector and the Health Services industry.

What is Replimune Group's Tenet Score?

Replimune Group's Tenet Score is 28 out of 100, ranked against 297 Healthcare peers as of Nov 13, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.